Pharma imports to U.S. surged in March ahead of tariffs, Reuters says

Pharmaceutical imports to the U.S. surged in March as drugmakers began to stock up ahead of potential U.S. tariffs on their products, Michael Erman of Reuters reports. Total imports of pharmaceutical products exceeded $50B in the month, the equivalent of 20% of all pharmaceutical imports in 2024. Imports specifically from Ireland jumped, with the country having a larger trade surplus than China with the U.S. for the first time in March. Publicly traded companies in the pharma space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).